Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Melinda Moree"'
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 6, Iss 8, p e1750 (2012)
Externí odkaz:
https://doaj.org/article/6f9168ee0e7b443f949636f230572ff7
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 6, Iss 10, p e1803 (2012)
Externí odkaz:
https://doaj.org/article/eceeb7c6155b41bf891e9364dacbff0b
Autor:
Sarah Ewart, Melinda Moree
Publikováno v:
The American Journal of Tropical Medicine and Hygiene. 71:248-252
Recently licensed life-saving vaccines have experienced slow introduction and gradual uptake in the developing world. Policy challenges at the national level contribute to the delay in making new vaccines accessible to people in poor countries. The h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7884279561eaa17272b6cb0bfdbb7541
https://doi.org/10.4269/ajtmh.2004.71.248
https://doi.org/10.4269/ajtmh.2004.71.248
Publikováno v:
Trends in parasitology. 22(7)
The misery and suffering caused worldwide by infection with the malaria parasite, especially Plasmodium falciparum, has been well documented. Although no licensed vaccine against malaria currently exists, progress has accelerated in recent years towa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cab5fcf000932eb52c7284d98f2676e
https://pubmed.ncbi.nlm.nih.gov/16707275
https://pubmed.ncbi.nlm.nih.gov/16707275
Publikováno v:
Nature. 430:938-939
The world must increase collaboration to meet the pressing need for a malaria vaccine, argue Carter Diggs, Sarah Ewart and Melinda Moree.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3249db58ad07eeadbee53dd3b450095
https://doi.org/10.1038/430938a
https://doi.org/10.1038/430938a
Publikováno v:
PLoS Neglected Tropical Diseases
PLoS Neglected Tropical Diseases, Vol 6, Iss 10, p e1803 (2012)
PLoS Neglected Tropical Diseases, Vol 6, Iss 10, p e1803 (2012)
The need for new drugs and vaccines for neglected tropical diseases (NTDs) is widely accepted [1]. Yet, encouraging pharmaceutical and biotechnology company investment in developing these much-needed treatments remains a challenge due to a lack of a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47776afb5cc4edb7e2754f8a6f08a1c1
https://doi.org/10.1371/journal.pntd.0001803
https://doi.org/10.1371/journal.pntd.0001803